Liana Lumi Ogino1, Elisa Baranski Lamback2, Alexandro Guterres1, Carlos Henrique de Azeredo Lima1, Daniel Gomes Henriques2, Monique Alvares Barbosa3, Débora Aparecida Silva1, Aline Helen da Silva Camacho1,4, Leila Chimelli1, Leandro Kasuki2,5,6, Mônica R Gadelha7,8,9. 1. Neuropathology and Molecular Genetics Laboratory - Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil. 2. Neuroendocrinology Research Center/ Endocrinology Division - Medical School and Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 3. Radiology Division - Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil. 4. Pathology Division - Instituto Nacional do Câncer, Rio de Janeiro, Brazil. 5. Neuroendocrinology Division - Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil. 6. Endocrinology Division - Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil. 7. Neuropathology and Molecular Genetics Laboratory - Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil. mgadelha@hucff.ufrj.br. 8. Neuroendocrinology Research Center/ Endocrinology Division - Medical School and Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. mgadelha@hucff.ufrj.br. 9. Neuroendocrinology Division - Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil. mgadelha@hucff.ufrj.br.
Abstract
PURPOSE: Non-functioning pituitary adenomas (NFPA) are benign tumors, however, some are agressive. We aimed to assess if human telomerase reverse transcriptase (hTERT) is present in NFPA and if it can be used as a marker of aggressiveness and proliferation. METHODS: Consecutive patients operated for NFPA whose fresh frozen tumors were available were included. We analyzed tumor's aggressiveness (based on radiological progression) and proliferation (based on Ki-67), as well as hTERT mRNA by quantitative real-time polymerase chain reaction (RT-qPCR). RESULTS: We included 109 samples from 86 patients followed for a median period of 60 months (5-120 months). Aggressive tumors were present in 66% cases and proliferative tumors in 47.7%. Seven (6.4%) samples expressed hTERT: 3 (42.8%) had aggressive and proliferative tumors, 2 (28.6%) only exhibited aggressiveness and the remaining 2 (28.6%) only proliferation. From the aggressive and proliferative tumors, 14% and 16%, respectively, expressed hTERT. From the non-aggressive and non-proliferative tumors, 9% and 6%, respectively, expressed hTERT. CONCLUSION: hTERT expression is present in a minority of NFPA and does not seem to be related to aggressiveness or proliferation in NFPA.
PURPOSE: Non-functioning pituitary adenomas (NFPA) are benign tumors, however, some are agressive. We aimed to assess if human telomerase reverse transcriptase (hTERT) is present in NFPA and if it can be used as a marker of aggressiveness and proliferation. METHODS: Consecutive patients operated for NFPA whose fresh frozen tumors were available were included. We analyzed tumor's aggressiveness (based on radiological progression) and proliferation (based on Ki-67), as well as hTERT mRNA by quantitative real-time polymerase chain reaction (RT-qPCR). RESULTS: We included 109 samples from 86 patients followed for a median period of 60 months (5-120 months). Aggressive tumors were present in 66% cases and proliferative tumors in 47.7%. Seven (6.4%) samples expressed hTERT: 3 (42.8%) had aggressive and proliferative tumors, 2 (28.6%) only exhibited aggressiveness and the remaining 2 (28.6%) only proliferation. From the aggressive and proliferative tumors, 14% and 16%, respectively, expressed hTERT. From the non-aggressive and non-proliferative tumors, 9% and 6%, respectively, expressed hTERT. CONCLUSION: hTERT expression is present in a minority of NFPA and does not seem to be related to aggressiveness or proliferation in NFPA.
Authors: Bernd W Scheithauer; Thomas A Gaffey; Ricardo V Lloyd; Thomas J Sebo; Kalman T Kovacs; Eva Horvath; Ozlem Yapicier; William F Young; Fredric B Meyer; Tamatsu Kuroki; Darren L Riehle; Edward R Laws Journal: Neurosurgery Date: 2006-08 Impact factor: 4.654
Authors: Gerald Raverot; Pia Burman; Ann McCormack; Anthony Heaney; Stephan Petersenn; Vera Popovic; Jacqueline Trouillas; Olaf M Dekkers Journal: Eur J Endocrinol Date: 2017-10-18 Impact factor: 6.664
Authors: Jacqueline Trouillas; Pascal Roy; Nathalie Sturm; Emmanuelle Dantony; Christine Cortet-Rudelli; Gabriel Viennet; Jean-François Bonneville; Richard Assaker; Carole Auger; Thierry Brue; Aurélie Cornelius; Henry Dufour; Emmanuel Jouanneau; Patrick François; Françoise Galland; François Mougel; François Chapuis; Laurent Villeneuve; Claude-Alain Maurage; Dominique Figarella-Branger; Gérald Raverot; A Barlier; M Bernier; F Bonnet; F Borson-Chazot; G Brassier; S Caulet-Maugendre; O Chabre; P Chanson; J F Cottier; B Delemer; E Delgrange; L Di Tommaso; S Eimer; S Gaillard; M Jan; J J Girard; V Lapras; H Loiseau; J G Passagia; M Patey; A Penfornis; J Y Poirier; G Perrin; A Tabarin Journal: Acta Neuropathol Date: 2013-02-12 Impact factor: 17.088